Updated on October 30th, 2024 by Felix Martinez
We believe long-term investors should focus on the highest-quality dividend growth stocks. These are companies with long histories of raising their dividends, and durable competitive advantages to fuel continued dividend growth.
Therefore, we tend to steer investors toward the Dividend Kings, a group of just 53 stocks with at least 50 years of dividend increases.
You can also download an Excel spreadsheet with the full list of all 53 Dividend Kings (plus important metrics such as price-to-earnings ratios and dividend yields) by clicking on the link below:
We review each of the Dividend Kings every year. The next stock to be reviewed in this year’s edition is AbbVie (ABBV).
There are questions regarding AbbVie’s future growth due to its flagship drug, Humira, facing patent expiration. However, the company has a plan to continue growing in the years ahead.
Business Overview
AbbVie is a global pharmaceutical giant. It began trading as an independent company in 2013 after being spun off from Abbott Laboratories (ABT). Since the spin-off, AbbVie has generated strong growth. According to AbbVie, revenue and adjusted EPS growth increased by 14.7% and 19%, respectively, each year from 2013 to 2021.
Today, AbbVie focuses on one main business segment—pharmaceuticals. It focuses on a few key treatment areas, including immunology, hematologic oncology, neuroscience, and more.
Source: Investor Presentation
Since the spin-off from Abbott, AbbVie has produced excellent growth, largely due to Humira, a multi-purpose drug. The challenge for AbbVie is that Humira is now facing biosimilar competition after it has lost patent exclusivity.
Even so, AbbVie remains a giant in the healthcare sector, with a large and diversified product portfolio.
AbbVie’s third-quarter financials for 2024 show a GAAP diluted EPS of $0.88, down 12%, but adjusted diluted EPS rose to $3.00, reflecting a 1.7% increase. The company posted $14.46 billion in net revenues, a 3.8% increase, driven primarily by its immunology, oncology, and neuroscience portfolios. The immunology portfolio, led by Skyrizi and Rinvoq, generated $7.046 billion in global revenues. Oncology and neuroscience also saw gains, with revenues of $1.687 billion and $2.363 billion, respectively, boosted by products like Imbruvica, Venclexta, Botox Therapeutic, and Vraylar.
AbbVie recently expanded its neuroscience portfolio by acquiring Cerevel, adding assets aimed at treating schizophrenia, Parkinson’s, and major depressive disorder. The acquisition complements AbbVie’s strategic goals, alongside recent FDA approvals for Vyalev, a subcutaneous infusion therapy for advanced Parkinson’s, and Botox Cosmetic for platysma bands, expanding its aesthetic applications. Additionally, AbbVie advanced its global presence, receiving European approval for Skyrizi in ulcerative colitis and Tepkinly for lymphoma treatment, strengthening its immunology and oncology offerings.
Looking forward, AbbVie raised its 2024 adjusted EPS guidance to $10.90-$10.94, reflecting confidence in its long-term growth. The company also announced a 5.8% dividend increase starting February 2025. CEO Robert A. Michael highlighted strong commercial performance and pipeline advancements as key factors supporting these adjustments. AbbVie continues leveraging new acquisitions, regulatory approvals, and strategic partnerships to enhance its portfolio and drive shareholder value.
Growth Prospects
The major risk for global pharmaceutical manufacturers is patent loss. When a particular drug loses patent, the market is typically flooded with competition, especially for the world’s top-selling products.
AbbVie’s biggest risk is the competition about to hit its flagship drug, Humira. This multi-purpose drug is used to treat a variety of conditions, including rheumatoid arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, and more.
Humira once generated over half of AbbVie’s annual sales. Loss of patent exclusivity is a significant overhang—AbbVie expects its total sales to decline in 2023 as a result. At the same time, AbbVie also expects to return to sales growth in 2025, with high single-digit annual growth through the end of the decade.
Fortunately, the company prepared for the loss of patent exclusivity on Humira by investing heavily in new products and acquisitions to boost its growth. For example, Rinvoq and Skyrizi are two key products that represent long-term growth catalysts.
Source: Investor Presentation
AbbVie also completed the $63 billion acquisition of Allergan. Allergan’s flagship product is Botox, which diversifies AbbVie’s portfolio by exposing it to global aesthetics.
We expect 5% EPS growth for AbbVie over the next five years, reflecting the steep patent cliff facing Humira. We believe the growth outlook will improve when the Humira overhang is gone, but there is uncertainty surrounding AbbVie’s ability to overcome that with new products.
Competitive Advantages & Recession Performance
The most important competitive advantage for AbbVie and any pharmaceutical company is its patent portfolio. Pharmaceutical giants need to spend heavily to develop new drugs and therapies, when one of their blockbusters loses patent protection.
AbbVie has over 80 clinical programs. It has multiple growth opportunities to replace Humira, particularly in the therapeutic areas of immunology, hematology, and neuroscience. The result of its significant investment in R&D is a well-stocked pipeline.
AbbVie was not a standalone company during the last financial crisis, so there is no recession track record. However, since sick people require treatment regardless of the economy’s strength, it is highly likely that AbbVie would continue to perform well during a recession.
AbbVie’s earnings are likely to decline somewhat in a recession, but the dividend should remain secure. AbbVie has a projected dividend payout ratio of ~57% for 2024.
Valuation & Expected Returns
AbbVie is expected to generate adjusted EPS of $10.92 for 2024 at the midpoint of guidance. At this EPS level, the stock currently has a price-to-earnings ratio of 17.4.
Our fair value estimate for AbbVie is a price-to-earnings ratio of 12, meaning the stock is over-valued today. A declining P/E multiple could reduce shareholder returns by approximately 7% per year over the next 5 years.
In addition, we expect annual earnings growth of 5% through 2029.
Lastly, the stock has a current dividend yield of 3.3%. Given these inputs, we expect annual returns of 1.3% per year over the next five years, making AbbVie stock a sell.
Final Thoughts
AbbVie is a very high-quality business, with a strong pharmaceutical pipeline and growth potential. It is also a shareholder-friendly company that returns excess cash flow to investors through stock buybacks and dividends.
AbbVie faces a significant challenge in replacing lost Humira sales as it faces competition in the U.S. and Europe. This is why we have fairly low assumptions for the company’s future EPS growth and fair value P/E multiple.
Still, the company has built a large portfolio of new products that should keep its growth intact. AbbVie will also be able to generate additional growth from the acquisition of Allergan.
However, the low expected returns make the stock a sell.
Additionally, the following Sure Dividend databases contain the most reliable dividend growers in our investment universe:
- The Dividend Champions: Dividend stocks with 25+ years of dividend increases, including those that may not qualify as Dividend Aristocrats.
- The Dividend Kings: considered to be the ultimate dividend growth stocks, the Dividend Kings list is comprised of stocks with 50+ years of consecutive dividend increases
If you’re looking for stocks with unique dividend characteristics, consider the following Sure Dividend databases:
- The Complete List of Monthly Dividend Stocks: stocks that pay dividends each month, for 12 payments over the year.
- The Blue Chip Stocks List: this database contains stocks that qualify as either Dividend Achievers, Dividend Aristocrats, or Dividend Kings.